Blood

Blood

  • Volume 2
  • Issue 52
  • ISSN 0006-4971
  • SCImago Journal Rank (SJR): 5.515
  • Source Normalized Impact per Paper (SNIP): 3.35
  • Impact Factor: 22.113
  • Five Year Impact Factor: 19.676
Editor-in-chief: Berliner

Subscription options

Sales tax will be calculated at check-out
Subscription length
Print - Rolling Subscription
Next planned ship date: Oct 21, 2021

Description

Blood, the flagship journal of the American Society of Hematology, published online and in print, provides an international forum for the publication of original articles describing basic laboratory, translational, and clinical investigations in hematology. Acceptance of manuscripts is based on the originality and importance of the observations or investigations, the quality of the work and validity of the evidence, the clarity of presentation, and the relevance to our readership and field. All articles are expected to be concise, well-organized and clearly written. Authors submit a manuscript with the understanding that the manuscript (or its essential substance) has not been published other than as an abstract in any language or format and is not currently submitted elsewhere for print or electronic publication.

Primary research articles will be published under the following scientific categories: Clinical Trials and Observations; Gene Therapy; Hematopoiesis and Stem Cells; Immunobiology and Immunotherapy; Myeloid Neoplasia; Lymphoid Neoplasia; Phagocytes, Granulocytes and Myelopoiesis; Platelets and Thrombopoiesis; Red Cells, Iron and Erythropoiesis; Thrombosis and Hemostasis; Transfusion Medicine; Transplantation; and Vascular Biology. Papers can be listed under more than one category as appropriate. Authors are invited to submit a presubmission inquiry if they are uncertain whether their work falls within the general scope of the journal.

Blood has formulated more precise scopes for immunobiology and immunotherapy, vascular biology, HIV/HTLV, and clinical trial submissions. The journal is very interested in submissions as reflected in the definitions linked below.



Blood welcomes submission of manuscripts reporting on clinical trials whether phase 1, 2, 3 or 4. Reports should include a full description of the study design, patient population, methodology and conduct, and statistical plan.

Immunobiology and Immunotherapy encompass a wide spectrum of research, but Blood can accommodate only papers that have clear and important implications for hematology. Preference is given to papers focusing on human immunobiology, immunotherapy, and immune pharmacology approaches in the human setting and those with significant implications for understanding of normal or malignant hematologic processes. Papers on tumor immunology, tumor vaccines and cancer immunotherapy development may be appropriate if the target cells or antigens are relevant to hematologic malignancies, but generally Blood cannot accommodate tumor immunology papers focusing solely on non-hematologic tumor types.

Papers investigating autoimmunity and utilizing non-hematologic models are not within the scope of Blood.

Vascular biology papers that focus primarily on atherosclerosis are outside the scope of Blood and instead should be considered for alternative journals.

Papers felt to be outside the scope of Blood will be returned to the author without full peer review.

Product details

  • SCImago Journal Rank (SJR): 5.515
  • Source Normalized Impact per Paper (SNIP): 3.35
  • Impact Factor: 22.113
  • Five Year Impact Factor: 19.676
  • ISSN: 0006-4971
  • Issues: 52
  • Volume: 2
Editorial board

Author services

Prepare your article for submission

Celebrate your publication

Additional services

Publication schedule

Issue volumeIssue yearPlanned ship dateActual ship date
137/12021Jan 07, 2021Jan 07, 2021
137/22021Jan 14, 2021Jan 13, 2021
137/32021Jan 21, 2021Jan 20, 2021
137/42021Jan 28, 2021Jan 28, 2021
137/52021Feb 04, 2021Feb 03, 2021
137/62021Feb 11, 2021Feb 10, 2021
137/72021Feb 18, 2021Feb 16, 2021
137/82021Feb 25, 2021Feb 25, 2021
137/92021Mar 04, 2021Mar 04, 2021
137/102021Mar 11, 2021Mar 11, 2021
137/112021Mar 18, 2021Mar 17, 2021
137/122021Mar 25, 2021Mar 25, 2021
137/132021Apr 01, 2021Apr 01, 2021
137/142021Apr 08, 2021Apr 08, 2021
137/152021Apr 15, 2021Apr 15, 2021
137/162021Apr 22, 2021Apr 22, 2021
137/172021Apr 29, 2021Apr 29, 2021
137/182021May 06, 2021May 06, 2021
137/192021May 13, 2021May 12, 2021
137/202021May 20, 2021May 20, 2021
137/212021May 27, 2021May 27, 2021
137/222021Jun 03, 2021Jun 03, 2021
137/232021Jun 10, 2021Jun 10, 2021
137/242021Jun 17, 2021Jun 17, 2021
137/252021Jun 24, 2021Jun 25, 2021
137/262021Jul 01, 2021Jul 01, 2021
138/12021Jul 08, 2021Jul 08, 2021
138/22021Jul 15, 2021Jul 15, 2021
138/32021Jul 22, 2021Jul 22, 2021
138/42021Jul 29, 2021Jul 29, 2021
138/52021Aug 05, 2021Aug 06, 2021
138/62021Aug 12, 2021Aug 12, 2021
138/72021Aug 19, 2021Aug 19, 2021
138/82021Aug 26, 2021Aug 26, 2021
138/92021Sep 02, 2021Sep 02, 2021
138/102021Sep 09, 2021Sep 10, 2021
138/112021Sep 16, 2021Sep 16, 2021
138/122021Sep 23, 2021Sep 23, 2021
138/132021Sep 30, 2021Sep 30, 2021
138/142021Oct 07, 2021Oct 07, 2021
138/152021Oct 14, 2021Oct 14, 2021
138/162021Oct 21, 2021
138/172021Oct 28, 2021
138/182021Nov 04, 2021
138/192021Nov 11, 2021
138/202021Nov 18, 2021
138/212021Nov 24, 2021
138/222021Dec 02, 2021
138/232021Dec 09, 2021
138/242021Dec 16, 2021
138/252021Dec 22, 2021
138/262021Dec 30, 2021
139/12022Jan 06, 2022
139/22022Jan 13, 2022
139/32022Jan 20, 2022
139/42022Jan 27, 2022
139/52022Feb 03, 2022
139/62022Feb 10, 2022
139/72022Feb 17, 2022
139/82022Feb 24, 2022
139/92022Mar 03, 2022
139/102022Mar 10, 2022
139/112022Mar 17, 2022
139/122022Mar 24, 2022
139/132022Mar 31, 2022
139/142022Apr 07, 2022
139/152022Apr 14, 2022
139/162022Apr 21, 2022
139/172022Apr 28, 2022
139/182022May 05, 2022
139/192022May 12, 2022
139/202022May 19, 2022
139/212022May 26, 2022
139/222022Jun 02, 2022
139/232022Jun 09, 2022
139/242022Jun 16, 2022
139/252022Jun 23, 2022
139/262022Jun 30, 2022
140/12022Jul 07, 2022
140/22022Jul 14, 2022
140/32022Jul 21, 2022
140/42022Jul 28, 2022
140/52022Aug 04, 2022
140/62022Aug 11, 2022
140/72022Aug 18, 2022
140/82022Aug 25, 2022
140/92022Sep 01, 2022
140/102022Sep 08, 2022
140/112022Sep 15, 2022
140/122022Sep 22, 2022
140/132022Sep 29, 2022
140/142022Oct 06, 2022
140/152022Oct 13, 2022
140/162022Oct 20, 2022
140/172022Oct 27, 2022
140/182022Nov 03, 2022
140/192022Nov 10, 2022
140/202022Nov 17, 2022
140/212022Nov 23, 2022
140/222022Dec 01, 2022
140/232022Dec 08, 2022
140/242022Dec 15, 2022
140/252022Dec 22, 2022
140/262022Dec 29, 2022